Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma

Cholangiocarcinoma is an intractable cancer, with no effective therapy other than surgical resection. Elevated vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) expressions are associated with the progression of cholangiocarcinoma. We therefore examined whether in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Yoshikawa, D, Ojima, H, Kokubu, A, Ochiya, T, Kasai, S, Hirohashi, S, Shibata, T
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2009
Matèries:
Translational Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2676540/
https://ncbi.nlm.nih.gov/pubmed/19319137
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604988
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars